{"id":963398,"date":"2026-05-15T06:37:41","date_gmt":"2026-05-15T10:37:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/"},"modified":"2026-05-15T06:37:41","modified_gmt":"2026-05-15T10:37:41","slug":"telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/","title":{"rendered":"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.<\/li>\n<li>Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.<\/li>\n<li>Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.<\/li>\n<\/ul>\n<p align=\"justify\">MELBOURNE, Australia and INDIANAPOLIS, May  15, 2026  (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, \u201cEDAP\u201d) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, \u201cProfound\u201d), leading companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix\u2019s commitment to advancing the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making.<\/p>\n<p align=\"justify\">The collaborations will explore the investigational use of Telix\u2019s PSMA-PET<sup>1<\/sup> imaging agents Gozellix\u00ae (kit for the preparation of gallium Ga 68 gozetotide) and Illuccix\u00ae (kit for the preparation of gallium Ga 68 gozetotide) with robotic high-intensity focused ultrasound (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qRZaZvuQFDzYTSvnQWJKL-ijZiJtIczoM_efO3Iyh52XSB_538h8zXSYI4piAyV3e---8-77GR0Jto7fWwCx4NByK181v6zPc12DDmQKCpg=\" rel=\"nofollow\" target=\"_blank\">HIFU<\/a>), and other image-guided therapies designed to treat localized prostate cancer, such as transurethral ultrasound ablation (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OLccpIaBvPw1ZGI2x3xl7a8rIFUuzgGHwGOn7qqTqd1TPKn3RBqC0MJYXECxf1Rymbu0xBwycgHbzbtFBxMwGzByIvFbXm2ql4Hv5_5lrDI=\" rel=\"nofollow\" target=\"_blank\">TULSA<\/a>).<\/p>\n<p align=\"justify\">Telix\u2019s intention is to work with select partners to explore how PSMA-PET imaging may support emerging therapy workflows, which aim to preserve healthy tissue and minimize the risk of side effects such as incontinence and impotence. Collaborative activities will focus on non-promotional scientific, educational, and research engagement<sup>2<\/sup>.<\/p>\n<p align=\"justify\">\u201cWe are uniquely designed to enable the integration of PSMA-PET imaging with Focal One\u2019s real-time ultrasound and fully robotic energy delivery to optimize treatment efficacy while minimizing side effects,\u201d said Ryan Rhodes, EDAP Chief Executive Officer. \u201cAs the market leader in robotic focal therapy, with a growing global installed base, this collaboration will accelerate the development and standardization of treatment strategies to further personalize focal therapy treatments using Telix\u2019s PSMA-PET imaging agents and Focal One Robotic HIFU.\u201d<\/p>\n<p align=\"justify\">\u201cEmerging clinical evidence suggests PSMA imaging may support prostate whole-gland, partial-gland, and focal ablation workflows, from treatment planning through post-treatment monitoring,\u201d said Arun Menawat, Profound\u2019s Chief Executive Officer and Chairman. \u201cIn collaboration with Telix, we look forward to exploring optimized workflows and generating clinical evidence that may help establish best practices and accelerate adoption of PSMA-PET imaging and the MRI-guided TULSA Procedure.\u201d<\/p>\n<p align=\"justify\">\u201cPrecision medicine requires precision treatment strategies,\u201d said Kevin Richardson, CEO, Telix Precision Medicine. \u201cAs disruptive technologies continue to transform prostate cancer care, we believe PSMA-PET imaging has the potential to play an important role in helping inform clinical decision-making across a range of minimally invasive and image-guided treatment approaches. We are excited to explore collaborations with market leaders in EDAP and Profound that may further advance personalized care for patients.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About EDAP TMS SA<\/strong>\n      <\/p>\n<p align=\"justify\">A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics, and precise non-invasive energy delivery, EDAP introduced the Focal One\u00ae in Europe and the United States as a leading prostate focal therapy platform controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vlzVT4eveXEDZYVTdJFjJHhKNWMWza3SW-FipwN8ezcqb6uSfB9ttAZEiFpUxakGI0PGdQentQpX1BjD5qTw3g==\" rel=\"nofollow\" target=\"_blank\">focalone.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Profound Medical Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures. The company\u2019s flagship platform,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OLccpIaBvPw1ZGI2x3xl7fuSU0JIDYiWF6dvL1H_aWLS-06m71drykX6Vwk_FI620HUIiUrsVDnCDSPo94KXuNpKpvzDkxhMLGiFgDqd4sq14y0sBxBYPoJPfAAdSntmO6A76z9yWrsFc0jYONRuOu-QbVeCXkJ7n6jSxxWaPIbUoopCV0hqgI_a1QeaA6Ks5uPvsicRc2-p0igRLwoYXxj9-ePdK5nOaW8n0KesvoDojPzhB7CFDlILPNejNXWH\" rel=\"nofollow\" target=\"_blank\">TULSA-PRO\u00ae<\/a>, enables MRI-guided, incision-free prostate ablation. Physicians use the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OLccpIaBvPw1ZGI2x3xl7f5STEMaYF38d5StdbLX0JvfM13EUMMNj11rp0T4DYflOGZEqRiVbL03ccZ8tmTug5PrF9e7UafhBbGrHjWK7G2tPJYGCYU50qxPID7Z9uFC7_xWdnTeQNwK3-yBRQVACdPzZSLEzKX8NTRecaeQIzxWDqR3Y6QYpS6Y-X_gR8HS1kTtqd3QSUb2-XMYhle_REg_B4XPvRGRN7UwM0DH0QdFpplYOJt0cxASSdwulFDRdzuUtAsMYAFZicQxNQkUE5R0X1MBd1JRUcjLAJKkooHwrguAwlCiqp5z_FjNq622r42vcRHnAvAPdotI5buQ6A==\" rel=\"nofollow\" target=\"_blank\">TULSA Procedure\u2122<\/a> to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care\u2014from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and\/or erectile dysfunction.<\/p>\n<p align=\"justify\">Profound Medical\u2019s technologies are approved across major global markets. TULSA-PRO is cleared by the FDA in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. In addition, TULSA-PRO is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia\/New Zealand, and the UAE.\u00a0<\/p>\n<p align=\"justify\">\n        <strong>IMPORTANT SAFETY INFORMATION (GOZELLIX)<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>WARNINGS AND PRECAUTIONS<\/strong><br \/>\n        <br \/>Risk for Misinterpretation<br \/>Image interpretation errors can occur with GOZELLIX PET. A negative image does not rule out the presence of prostate cancer, and a positive image does not confirm the presence of prostate cancer. Gallium Ga-68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget\u2019s disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.<\/p>\n<p align=\"justify\">\n        <u>Imaging Prior to Initial Definitive or Suspected Recurrence Therapy<\/u><br \/>\n        <br \/>The performance of GOZELLIX for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of GOZELLIX for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score.<\/p>\n<p align=\"justify\">Radiation Risks<br \/>Gallium Ga-68 gozetotide contributes to a patient\u2019s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration.<\/p>\n<p align=\"justify\">\n        <strong>Hypersensitivity Reactions to Sulfites<\/strong><br \/>\n        <br \/>Ascorbic Acid Stabilizer contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.<\/p>\n<p align=\"justify\">\n        <strong>ADVERSE REACTIONS<\/strong><br \/>\n        <br \/>The safety of gallium Ga-68 gozetotide was evaluated in 960 patients in the PSMA-PreRP and PSMABCR studies, each receiving one dose of gallium Ga-68 gozetotide. The average injected activity was 188.7 \u00b1 40.7 MBq (5.1 \u00b1 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of &lt;1%.<\/p>\n<p align=\"justify\">\n        <strong>DRUG INTERACTIONS<\/strong><br \/>\n        <br \/>Androgen deprivation therapy and other therapies targeting the androgen pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga-68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga-68 gozetotide PET has not been established.<\/p>\n<p align=\"justify\">\n        <strong>Please note that this information is not comprehensive.<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Please see the Full Prescribing Information <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HYjhWqgYcWuBw3rpEfM8-hn8l7KhNunCy3ulamPLUiq_S_trmvpIo7CpNCh2Ic2ez_28--CWpLRm7p0IH3H1pee7yTg6bJXssYi-2nLJ7JH5ho3d-B1Xqe2eM-5HreHj56Ppt4bgQUYxb5RC7TG71KFaAs1TuspymkXME9eaqhk=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>here<\/strong><br \/>\n        <\/a><br \/>\n        <strong>.<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>IMPORTANT SAFETY INFORMATION (ILLUCCIX)<\/strong><br \/>\n        <br \/>\n        <strong>WARNINGS AND PRECAUTIONS<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Risk for Misinterpretation<\/strong><br \/>\n        <br \/>Image interpretation errors can occur with Illuccix PET. A negative image does not rule out the presence of prostate cancer, and a positive image does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget\u2019s disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.<\/p>\n<p align=\"justify\">\n        <u>Imaging Prior to Initial Definitive or Suspected Recurrence Therapy<\/u><br \/>\n        <br \/>The performance of Illuccix for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of Illuccix for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score.<\/p>\n<p align=\"justify\">\n        <strong>Radiation Risks<\/strong><br \/>\n        <br \/>Gallium Ga 68 gozetotide contributes to a patient\u2019s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration.<\/p>\n<p align=\"justify\">\n        <strong>ADVERSE REACTIONS<\/strong><br \/>\n        <br \/>The safety of gallium Ga 68 gozetotide was evaluated in 960 patients in the PSMA-PreRP and PSMA-BCR studies, each receiving one dose of gallium Ga 68 gozetotide. The average injected activity was 188.7 \u00b1 40.7 MBq (5.1 \u00b1 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of &lt;1%.<\/p>\n<p align=\"justify\">In the VISION study, 1003 patients received one dose of gallium Ga 68 gozetotide intravenously with the amount of radioactivity 167.1 \u00b1 23.1 MBq (4.52 \u00b1 0.62 mCi). Adverse reactions occurring at \u22650.5% in patients with metastatic prostate cancer who received gallium Ga 68 gozetotide injection in the clinical study were fatigue (1.2%), nausea (0.8%), constipation (0.5%), and vomiting (0.5%).<br \/>Adverse reactions occurring at a rate of &lt; 0.5% in the VISION study were diarrhea, dry mouth, injection site reactions, including injection site hematoma and injection site warmth and chills.<\/p>\n<p align=\"justify\">Injection site pain has been identified during postapproval use of ILLUCCIX.<strong><br \/><\/strong><\/p>\n<p align=\"justify\">\n        <strong>DRUG INTERACTIONS<\/strong><br \/>\n        <br \/>\n        <u>Androgen deprivation therapy and other therapies targeting the androgen pathway<\/u><br \/>\n        <br \/>Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established.<\/p>\n<p>\n        <strong>Please note that this information is not comprehensive.<\/strong><br \/>\n        <br \/>\n        <strong>Please see the Full Prescribing Information <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HYjhWqgYcWuBw3rpEfM8-hg3OqPdRU7nqaCPMQFVqFQW_xrOBFbSHSiGhZx7iJV3K6fYWzn57P7v5BXhOrBiG1WYyuko2PFwwWNHzVebRNcytA3TtVBc3AhYHGFf10IgnsXfgygrWDrt72T-c2g2JvOyPPI-y7UrdQCPbSjBd2E=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>here<\/strong><br \/>\n        <\/a><br \/>\n        <strong>.<\/strong>\n      <\/p>\n<p>\n        <strong>You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at\u00a0<\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wNavEwpyA6zw3nRcXm74nmBbKaUceXRaYYYEmgSZNTo-IezjB6o72ONyfpL1up5EFYg9qb-D1rjeZ_jlHE7TmKBgaf4rzPbnT5fJFM8vtlc=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>www.fda.gov\/medwatch<\/strong><br \/>\n        <\/a><br \/>\n        <strong>\u00a0or call\u00a0<\/strong><br \/>\n        <strong>1-800-FDA-1088<\/strong><br \/>\n        <strong>.<\/strong>\u00a0You may also report adverse reactions to Telix by calling\u00a01-844-455-8638\u00a0or emailing: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G7hmapaGDislrb7ujQ5K58XzNpaca2fDyNmfQJcngnnPnHMImP2XxqY4nRGeE8dN6pxc3sX3ZlJ7glF0pcx7iNOScAY7yhw6IgYsAF4UKEEh929P2lDivsXFV31x9BnmSkwV96KuC_l_BBIcUGpNuQ==\" rel=\"nofollow\" target=\"_blank\">pharmacovigilance@telixpharma.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>Telix Pharmaceuticals Limited <\/strong>\n      <\/p>\n<p align=\"justify\">Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).<\/p>\n<p align=\"justify\">Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bo3ZYaNwvchep1C8cVNGyY8hSC_yWHX3dzl3KIVYeNq5fsx8qFR-gokDWvK3fDvRbqtnNC5VJ6owRUyKDRRcjOQFRWnIYnmjg5h25fJovjw=\" rel=\"nofollow\" target=\"_blank\">www.telixpharma.com<\/a> for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8RAxpQE281qZBv7Myxuj4LJOpRqiRgZhBhmXhxQJ3TqcX9eUlF0GcH-cMUXZ4RHUMOfqQrgpYNzXpplq0ugNui-iDy9GC2McX5DdRhbUDZYzeQTS_GF9caGj8h_hqDKP\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BiWTOqXfoZVFYtzB8yxs5SpcpUajWUdmm2Zadgr8LLKh06h84aqScbu7EhV-3EQaJHlJL6gLBZUnAkGai3-dDA==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TdTZpuCGdgpkR4ZcSblk9MOe5y8HBhekGumwt8L8hkS2Nt1lm_QWPf01eeF_k_KHQb1a9nK1qzGnkjgoLD_kJkM69RNuT_b4V58OBRboOEg=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:37%;width:37%;min-width:37%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Telix Investor Relations (Global)<\/strong><\/p>\n<p>Ms. Kyahn Williamson<br \/>SVP Investor Relations and Corporate Communications<br \/><a href=\"mailto:kyahn.williamson@telixpharma.com\" rel=\"nofollow\" target=\"_blank\">kyahn.williamson@telixpharma.com<\/a><\/td>\n<td style=\"max-width:24%;width:24%;min-width:24%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Telix Investor Relations (Australia)<\/strong><\/p>\n<p>Ms. Charlene Jaw<br \/>Associate Director Investor\u00a0Relations<br \/><a href=\"mailto:charlene.jaw@telixpharma.com\" rel=\"nofollow\" target=\"_blank\">charlene.jaw@telixpharma.com<\/a><\/td>\n<td style=\"max-width:39%;width:39%;min-width:39%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Telix Investor Relations (U.S.)\u202f\u00a0<\/strong><\/p>\n<p>Ms. Annie Kasparian\u202f\u00a0<br \/>Director Investor Relations and Corporate Communications\u202f\u00a0<br \/><a href=\"mailto:annie.kasparian@telixpharma.com\" rel=\"nofollow\" target=\"_blank\">annie.kasparian@telixpharma.com<\/a>\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Telix Media Contact (U.S.)<\/strong><\/p>\n<p>Eliza Schleifstein<br \/>917.763.8106 (Mobile)<br \/><a href=\"mailto:Eliza@schleifsteinpr.com\" rel=\"nofollow\" target=\"_blank\">Eliza@schleifsteinpr.com<\/a><\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>EDAP Investor Relations<\/strong><\/p>\n<p>Louisa Smith<br \/>Gilmartin Group<br \/><a href=\"mailto:investor.relations@focalone.com\" rel=\"nofollow\" target=\"_blank\">investor.relations@focalone.com<\/a><\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Profound Investor Relations<\/strong><\/p>\n<p>Stephen Kilmer<br \/>647.872.4849 (Mobile)<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DmOKQuAynP46gR4S3oUsfDTJIKhR5T3wNkUV3uF11D_JmA57iG2lwWZLSR4rypsMPvFJ8ziqitmgpW5YcApZn0c0GyJPxG8POa3iGNDViMxhi7LavyIEtmjXlFWUTrkk\" rel=\"nofollow\" target=\"_blank\">skilmer@profoundmedical.com<\/a>\u00a0\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <br \/>Legal Notices<\/p>\n<p align=\"center\">\n        <em>Cautionary Statement Regarding Forward-Looking Statements.\u00a0 <\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <em>You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as \u201cmay\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cplan\u201d, \u201cestimate\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201coutlook\u201d, \u201cforecast\u201d and \u201cguidance\u201d, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix\u2019s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix\u2019s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix\u2019s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix\u2019s preclinical and clinical trials, and Telix\u2019s research and development programs; Telix\u2019s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix\u2019s product candidates, manufacturing activities and product marketing activities; Telix\u2019s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix\u2019s product candidates, if or when they have been approved; Telix\u2019s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix\u2019s expenses, future revenues and capital requirements; Telix\u2019s financial performance; developments relating to Telix\u2019s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix\u2019s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix\u2019s product candidates, if and after they have been approved. Telix\u2019s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the \u00ae or \u2122 symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>\u00a92026 Telix Pharmaceuticals Limited. All rights reserved.<\/em>\n      <\/p>\n<p>\n        <sup>______________________________________<br \/><\/sup><br \/>\n        <sup>1<\/sup> Imaging of prostate-specific membrane antigen.<br \/><sup>2<\/sup> PSMA-PET imaging is not currently approved for specific treatment-planning indications associated with these emerging therapies.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTdhYjc3OTktNWJmZi00MGQ1LWE3ZjQtZTYzZGExMWQ0NTU3LTEwOTQ4MTMtMjAyNi0wNS0xNS1lbg==\/tiny\/Telix-Pharmaceuticals-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice. Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes. MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, \u201cEDAP\u201d) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, \u201cProfound\u201d), leading companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-963398","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice. Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes. MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, \u201cEDAP\u201d) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, \u201cProfound\u201d), leading companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix\u2019s &hellip; Continue reading &quot;Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-15T10:37:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches\",\"datePublished\":\"2026-05-15T10:37:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/\"},\"wordCount\":2416,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/\",\"name\":\"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI=\",\"datePublished\":\"2026-05-15T10:37:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/","og_locale":"en_US","og_type":"article","og_title":"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - Market Newsdesk","og_description":"Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice. Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes. MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, \u201cEDAP\u201d) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, \u201cProfound\u201d), leading companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix\u2019s &hellip; Continue reading \"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-15T10:37:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches","datePublished":"2026-05-15T10:37:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/"},"wordCount":2416,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/","name":"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI=","datePublished":"2026-05-15T10:37:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyMTAyOSM3NjAzNDg0IzIwODMyNDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=963398"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/963398\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=963398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=963398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=963398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}